# Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction

> **NCT01912222** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Advanced Solid Tumors
- Hematologic Malignancies

## Interventions

- **DRUG:** IXAZOMIB

## Key facts

- **NCT ID:** NCT01912222
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01912222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01912222, "Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01912222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*